BioSpace - Esperion Therapeutics, Inc. News, Search Jobs, Events

BioSpace.com

Biotech and Pharmaceutical
News & Jobs

Search the Site

Employers
Post Job | Search Resumes | Login

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile

..

Esperion Therapeutics, Inc.

3621 S. State Street
695 KMS Place
Ann Arbor Michigan 48108 U.S.A.
Phone: 734-332-0506 Fax: 734-332-0516

Esperion Therapeutics, Inc., is a biopharmaceutical company dedicated to the discovery, development and commercialization of a novel class of therapies to treat cardiovascular and metabolic diseases, including atherosclerosis, as they relate to high density lipoprotein cholesterol, "HDL-C", also known as the "good" cholesterol.

The technology platform for Esperion is based upon the Reverse Lipid Transport (RLT) pathway. The RLT pathway is responsible for removing excess cholesterol and other lipids from arterial walls and other tissues for transport to the liver and elimination from the body. The Company's product candidates work by stimulating the RLT pathway through the enhancement of key HDL properties, which may result in improved vascular structure and function. Esperion is focusing its efforts on developing both acute and chronic therapies for cardiovascular and metabolic diseases.

Esperion was founded in 1998 by, among others, members of the Warner-Lambert/Parke-Davis (now Pfizer) team that discovered and developed atorvastatin, the highly successful multibillion-dollar drug. Since that time, an additional group of exceptional scientists and specialists has joined the Company. Many of these individuals have been instrumental in the discovery, development and commercialization of several of the pharmaceutical industry's most successful therapies. It is this combined team that makes Esperion a leading enterprise in HDL drug discovery and research.

Key Management:

Roger Newton, Ph.D.
President and CEO

Timothy Mayleben
Chief Operating Officer and CFO

Last Updated: 01-18-05

Key Statistics

Email: info@esperion.com
Ownership: Private

Web Site: Esperion Therapeutics, Inc.
Employees:
Symbol:

Industry
Biotechnology

Company News

Esperion Therapeutics, Inc. Announces Positive Top-Line Results From Phase 2 Clinical Study of Novel Oral Therapy in Patients With Hypercholesterolemia and a History of Statin Intolerance 6/7/2013 9:53:26 AM More...

Esperion Therapeutics, Inc. Files for $70 Million IPO 5/16/2013 7:30:19 AM More...

Esperion Therapeutics, Inc. Presents Full Results of Phase 2 Clinical Trial Showing Its Novel Oral Therapy ETC-1002 Lowered LDL-C By Up to 43 Pct in Hypercholesterolemic Patients With Type 2 Diabetes 5/3/2013 11:04:59 AM More...

Esperion Therapeutics, Inc. Completes $33 Million Preferred Financing 4/25/2013 7:07:45 AM More...

Esperion Therapeutics, Inc. Announces Positive Topline Results from a Phase 2 Clinical Trial of ETC-1002 in Patients with Type 2 Diabetes 1/7/2013 9:58:17 AM More...

Tim Mayleben Named President and CEO of Esperion Therapeutics, Inc. 1/4/2013 7:28:37 AM More...

Esperion Therapeutics, Inc. to Present at 31st Annual J.P. Morgan Healthcare Conference 1/4/2013 6:38:22 AM More...

Noah Rosenberg, MD, Joins Esperion Therapeutics, Inc. as Chief Medical Officer 4/10/2012 8:38:29 AM More...

Esperion Therapeutics, Inc. Announces Positive Phase 2 Clinical Trial Results for ETC-1002 3/26/2012 7:45:36 AM More...

Esperion Therapeutics, Inc. Announces Results From Phase 1 Study and Four Preclinical Studies for ETC-1002 5/2/2011 7:19:55 AM More...

1